Henlius Reports First Patient Dosing in P-II/III Study of HLX10 + HLX04 (biosimilar- bevacizumab) for 1L mCRC
Shots:
- The first patient has been dosed in a P-II/III clinical trial of HLX10 in combination with HLX04 (bevacizumab) and CT for 1L treatment of mCRC
- The combination regimen aims to benefit patients with I-O mAbs combination therapy as early as possible- further delaying the disease progression and improving the survival status of patients with mCRC
- HLX10 is a recombinant humanized anti- PD-1 mAb injection. HLX10 in combination with HLX04 is the first domestic mAbs combination therapy approved for clinical trials in China- which has been carried out late-stage clinical studies in NSCLC and HCC previously
Ref: Henlius | Image: Henlius
Click here to read the full press release
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].
